Liza Brown
Dermatology · Trinity, FLNPI 1487064580
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 68.2% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $15,186, more than ten times the $610 reported in 2019. Among dermatology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $54.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$20K
- AbbVie$2K
- Regeneron Healthcare Solutions, Inc.$954
- Novartis$714
- UCB, Inc.$693
- Lilly USA, LLC$636
- plus $5K from 25 others
What the payments were for
- Speaking & faculty fees$17,11859%
- Food & beverage$11,18339%
- Education$6282%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 110 | $19,736 |
| AbbVie(2 entities) | 101 | $1,586 |
| Regeneron Healthcare Solutions, Inc. | 31 | $954 |
| Novartis | 29 | $714 |
| UCB, Inc. | 32 | $693 |
| Lilly USA, LLC | 25 | $636 |
| Pfizer | 28 | $619 |
| LEO Pharma Inc. | 27 | $571 |
| Sanofi | 18 | $503 |
| Mayne Pharma Commercial LLC | 23 | $468 |
| E.r. Squibb & Sons, L.L.C. | 20 | $354 |
| Galderma Laboratories, L.p. | 13 | $329 |
| Sun Pharmaceutical Industries Inc. | 17 | $320 |
| Incyte Corporation | 9 | $208 |
| Boehringer Ingelheim | 7 | $190 |
| Amgen | 8 | $160 |
| Organogenesis Inc. | 6 | $156 |
| Prugen, Inc. Pharmaceuticals | 1 | $134 |
| Biofrontera Inc. | 6 | $105 |
| Almirall LLC | 4 | $79 |
| Arcutis Biotherapeutics, Inc. | 4 | $76 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $73 |
| Journey Medical Corporation | 2 | $57 |
| Hill Dermaceuticals, Inc. | 1 | $42 |
| Dermavant Sciences, Inc. | 2 | $41 |
| Botanix SB Inc | 2 | $37 |
| DUSA Pharmaceuticals, Inc. | 1 | $22 |
| VYNE Pharmaceuticals Inc. | 1 | $22 |
| Verrica Pharmaceuticals Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $18 |
| Organon | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,929 in reported general payments places this provider in the 90th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 12 | $58,206 |
| Dupixent PenDupilumab | 15 | $56,961 |
| OpzeluraRuxolitinib Phosphate | 11 | $22,450 |
| Doxycycline Hyclate | 84 | $6,487 |
| Clobetasol Propionate | 54 | $2,266 |
| Ketoconazole | 107 | $1,579 |
| Triamcinolone Acetonide | 137 | $1,440 |
| Mupirocin | 141 | $810 |
| Fluocinonide | 20 | $707 |
| Clindamycin Phosphate | 24 | $686 |
| Cephalexin | 33 | $607 |
| Minoxidil | 51 | $598 |
| Nystatin | 37 | $444 |
| ValacyclovirValacyclovir Hcl | 28 | $283 |
| Glycopyrrolate | 16 | $277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $160 | $58,20612 claims |
| Incyte CorporationOpzelura | $208 | $22,45011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Trinity
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.